Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Next Previous
Trial Profile

KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mivocabtagene autoleucel (Primary)
  • Indications Diffuse scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KYSA-5
  • Sponsors Kyverna Therapeutics

Most Recent Events

  • 08 Oct 2025 Status changed from recruiting to active, no longer recruiting.
  • 13 Nov 2024 According to a Kyverna Therapeutics media release, Kyverna initiated dosing in KYSA-5, the Company's Phase 1/2 study in systemic sclerosis.
  • 15 Aug 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top